Reference is made to Lifecare AS (LIFE) stock exchange notification 6 February
2023.

Today, Lifecare is pleased to announce that a sensor first used in our ongoing
Clinical Development Study has confirmed an operational longevity of 12 weeks in
a continued laboratory (in vitro) set up. This is yet another important
milestone in the development of our Sencell technology for Continuous Glucose
Monitoring (CGM). 

The achievement was made possible through the use of a sensor that was first
implanted and tested clinically in human (in vivo), and then explanted and
transferred to continued testing in vitro. The operational longevity in this
combined in vivo and in vitro experiment has passed 12 weeks and is still
ongoing.   

This innovative approach allowed Lifecare to demonstrate the longevity of the
Sencell sensor in a more realistic and relevant environment, as well as to
document an impressive sensor robustness. The experiment also confirms the
stability of the chemistry used in the in the sensor and demonstrates that the
technology has a superior longevity compared to existing needle-based CGM
sensors.

The 12-week longevity achievement is an important confirmation towards
Lifecare's main goal of achieving a longevity of 6 months or more in vivo for
its Sencell sensor. It confirms the potential of the technology to provide
long-term and accurate glucose monitoring for people with diabetes, while
reducing the need for frequent sensor replacements.

-We are satisfied to tick-off yet another achievement confirming that we are on
track with our development to provide a long-term and accurate Continuous
Glucose Monitor for people with diabetes, Lifecare strive to ensure high quality
in all stages of our development, and this ongoing experiment forms an important
and reassuring base for our upcoming clinical longevity study, says Joacim
Holter, CEO of Lifecare.

******

Lifecare AS is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on
the sensor body for read-out of pressure variations. LifecareŽs sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the human
body.

******

For further information, please contact: 
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Joacim Holter, CEO at Lifecare AS, on 11 April
2023 at 8:15 AM CET.